Nextage Therapeutics (Israel) Performance
| MCTC Stock | ILA 71.00 3.00 4.41% |
Nextage Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.74, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Nextage Therapeutics are expected to decrease at a much lower rate. During the bear market, Nextage Therapeutics is likely to outperform the market. Use Nextage Therapeutics maximum drawdown, potential upside, semi variance, as well as the relationship between the value at risk and downside variance , to analyze future returns on Nextage Therapeutics.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Nextage Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Nextage Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 481 K | |
| Total Cashflows From Investing Activities | 13 K | |
| Discontinued Operations | -23 K |
Nextage |
Nextage Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,110 in Nextage Therapeutics on January 20, 2024 and sell it today you would earn a total of 2,990 from holding Nextage Therapeutics or generate 72.75% return on investment over 90 days. Nextage Therapeutics is generating 1.5023% of daily returns and assumes 10.1795% volatility on return distribution over the 90 days horizon. Simply put, 90% of stocks are less volatile than Nextage, and 71% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Nextage Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nextage Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nextage Therapeutics, and traders can use it to determine the average amount a Nextage Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1476
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | MCTC | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.18 actual daily | 90 90% of assets are less volatile |
Expected Return
| 1.5 actual daily | 29 71% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Nextage Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nextage Therapeutics by adding it to a well-diversified portfolio.
Nextage Therapeutics Fundamentals Growth
Nextage Stock prices reflect investors' perceptions of the future prospects and financial health of Nextage Therapeutics, and Nextage Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nextage Stock performance.
| Return On Asset | -0.37 | |||
| Profit Margin | (2.30) % | |||
| Operating Margin | (9.71) % | |||
| Shares Outstanding | 2.27 M | |||
| Price To Earning | (91.98) X | |||
| Price To Book | 4.68 X | |||
| Price To Sales | 26.11 X | |||
| Revenue | 297 K | |||
| EBITDA | (5.38 M) | |||
| Cash And Equivalents | 358 K | |||
| Cash Per Share | 0.16 X | |||
| Debt To Equity | 65.70 % | |||
| Book Value Per Share | 0.90 X | |||
| Cash Flow From Operations | (5 M) | |||
| Earnings Per Share | (0.24) X | |||
| Total Asset | 6.01 M | |||
| Retained Earnings | (103 M) | |||
| Current Asset | 3 M | |||
| Current Liabilities | 2 M | |||
About Nextage Therapeutics Performance
To evaluate Nextage Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Nextage Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Nextage Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Nextage Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Nextage's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.Things to note about Nextage Therapeutics performance evaluation
Checking the ongoing alerts about Nextage Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nextage Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nextage Therapeutics is way too risky over 90 days horizon | |
| Nextage Therapeutics appears to be risky and price may revert if volatility continues | |
| The company has 0.0 in debt which may indicate that it relies heavily on debt financing | |
| The company has a current ratio of 0.43, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Nextage Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Nextage Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nextage Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nextage to invest in growth at high rates of return. When we think about Nextage Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Nextage Therapeutics reported the revenue of 297 K. Net Loss for the year was (2.09 M) with profit before overhead, payroll, taxes, and interest of 207 K. | |
| Nextage Therapeutics has accumulated about 358 K in cash with (5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Nextage Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nextage Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Nextage Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nextage Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nextage Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nextage Therapeutics' stock. These opinions can provide insight into Nextage Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nextage Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Nextage Stock analysis
When running Nextage Therapeutics' price analysis, check to measure Nextage Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nextage Therapeutics is operating at the current time. Most of Nextage Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nextage Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nextage Therapeutics' price. Additionally, you may evaluate how the addition of Nextage Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |